High expression of pdl-1 in patients with triple negative breast cancer with residual tumor burden after neoadjuvant chemotherapy.

被引：1
|
作者：
Oner, Gizem [1 ]
Onder, Semen [1 ]
Karatay, Huseyin [1 ]
Tukenmez, Mustafa [1 ]
Muslumanoglu, Mahmut [1 ]
Igci, Abdullah [1 ]
Dinccag, Ahmet [1 ]
Ozmen, Vahit [1 ]
Aydiner, Adnan [1 ]
Yavuz, Ekrem [1 ]
Cabioglu, Neslihan [1 ]
机构：
[1] Istanbul Univ, Istanbul, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e24136
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e24136
引用
收藏
页数：1
相关论文
共 50 条
  • [41] An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy
    Blaye, C.
    Darbo, E.
    Debled, M.
    Brouste, V.
    Velasco, V.
    Pinard, C.
    Pellegrin, I.
    Tarricone, A.
    Arnedos, M.
    Commeny, J.
    Bonnefoi, H.
    Larmonier, C.
    Macgrogan, G.
    ANNALS OF ONCOLOGY, 2022, 33 : S127 - S127
  • [42] Circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC)
    Lucci, A.
    Hall, C.
    Hess, K.
    Ravenberg, E.
    Clayborn, A.
    Mittendorf, E.
    Rauch, G.
    Candelaria, R.
    Moulder, S.
    Thompson, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [43] Adjuvant treatment for triple negative breast cancer with residual tumor after neo-adjuvant chemotherapy. A single institutional retrospective analysis
    Bianco, Nadia
    Palazzo, Antonella
    Pagan, Eleonora
    Bagnardi, Vincenzo
    Milano, Monica
    De Maio, Ana Paula
    Colleoni, Marco
    BREAST, 2021, 59 : 351 - 357
  • [44] Biomarker identification of residual triple negative breast cancer (TNBC) after standard neoadjuvant chemotherapy (NCT)
    Sohn, Joohyuk
    Liu, Shuyling
    Chen, Huiqin
    Meng, Xiaolong
    Kim-Anh Do
    Mills, Gordon B.
    Hortobagyi, Gabriel N.
    Meric-Bernstam, Funda
    Gonzalez-Angulo, Ana M.
    CANCER RESEARCH, 2012, 72
  • [45] Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy
    Sohn, J.
    Do, K. A.
    Liu, S.
    Chen, H.
    Mills, G. B.
    Hortobagyi, G. N.
    Meric-Bernstam, F.
    Gonzalez-Angulo, A. M.
    ANNALS OF ONCOLOGY, 2013, 24 (10) : 2522 - 2526
  • [46] Pathologic and immunohistochemical prognostic score in residual triple-negative breast cancer after neoadjuvant chemotherapy
    Ilie, S. M.
    Arnould, L.
    Briot, N.
    Desmoulins, I.
    Hennequin, A.
    Kaderbhai, C.
    Bertaut, A.
    Coutant, C.
    Causeret, S.
    Loustalot, C.
    Ilie, A.
    Derangere, V.
    Ladoire, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S432 - S432
  • [47] Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy
    Ilie, Silvia Mihaela
    Briot, Nathalie
    Constatin, Guillaume
    Ilie, Alis
    Beltjens, Francoise
    Ladoire, Sylvain
    Desmoulins, Isabelle
    Hennequin, Audrey
    Bertaut, Aurelie
    Coutant, Charles
    Causeret, Sylvain
    Ghozali, Niama
    Coudert, Bruno
    Arnould, Laurent
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [48] Pretreatment neutrophil to lymphocyte ratio (NLR) in patients with triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy.
    Walker, Paul R.
    Hildebrand, Jessica R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] Treatment outcomes in triple negative breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67
    Rapoport, Bernardo Leon
    Barnard-Tidy, Jacqui
    van Eeden, Ronwyn
    Smit, Teresa
    Nayler, Simon
    Benn, Carol
    CANCER RESEARCH, 2020, 80 (04)
  • [50] Use of tumoral LDH to predict residual tumor burden after neoadjuvant chemotherapy in breast cancer.
    Lee, Soo Jung
    Lee, In Hee
    Kang, Byeongju
    Park, Jee-Young Nora
    Lee, Jeeyeon
    Park, Ho Yong
    Park, Ji-Young
    Chae, Yee Soo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345